MDMichael Dzuricky

Michael Dzuricky

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael Dzuricky has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Ashutosh Chilkoti

    Department of Biomedical Engineering Duke University Durham North Carolina USA

    9 shared publications
  • Patrick Weber

    Tissue Engineering & Biofabrication Laboratory, Department of Health Sciences and Technology, ETH Zurich, Otto-Stern-Weg 7, 8093 Zurich, Switzerland

    3 shared publications
  • Ashutosh Chilkoti

    Department of Biomedical Engineering , Duke University , Durham , North Carolina 27708-0281 , United States

    2 shared publications
  • Davoud Mozhdehi

    Department of Biomedical Engineering , Duke University , 1427 FCIEMAS , Box 90281, Durham , North Carolina 27708-0281 , United States

    2 shared publications
  • Ivan Spasojevic

    Duke University School of Medicine, Department of Medicine Oncology and Duke Cancer Institute PK/PD Core Laboratory, Durham, North Carolina 27710, United States

    2 shared publications
  • Jayanta Bhattacharyya

    Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, North Carolina 27708, United States

    2 shared publications

Latest Publications

  • Genetically Engineered Nanoparticles of Asymmetric Triblock Polypeptide with a Platinum(IV) Cargo Outperforms a Platinum(II) Analog and Free Drug in a Murine Cancer Model

    by Soumen Saha, Samagya Banskota, Jianqiao Liu, Nikita Zakharov, Michael Dzuricky, Xinghai Li, Ping Fan, Sonal Deshpande, Ivan Spasojevic, Kedar Sharma, et al.

    Despite the widespread use of platinum(Pt)-drugs for cancer-therapy, their development has stalled, as no new Pt-drugs have been approved in over a decade. Packaging small molecule drugs into nanoparticles is a way to enhance their therapeutic efficacy. However, an important consideration in designing Pt-nanoparticles, and the focus of this study, is the rational choice of oxidation-state of Pt. To date, there has been no direct comparison of relative merits of the choice of Pt oxidation-state in the same nanoparticle-system that would allow its optimal design. To address this lacuna, we designed an recombinant asymmetric triblock polypeptide (ATBP) that self-assembles into rod-shaped micelles and chelates Pt(II) or enable covalent conjugation of Pt(IV) with similar morphology and stability. Both ATBP-Pt(II) and ATBP-Pt(IV) nanoparticles enhanced the half-life of Pt by ~45-fold but ATBP-Pt(IV) had superior tumor regression efficacy compared to ATBP-Pt(II) and cisplatin. These results suggest loading Pt(IV) into genetically engineered nanoparticles may yield a new generation of more effective platinum-drug nanoformulations.


  • Concentration-Independent Multivalent Targeting of Cancer Cells by Genetically Encoded Core-Crosslinked Elastin/Resilin-like Polypeptide Micelles

    by Patrick Weber, Michael Dzuricky, Junseon Min, Irene Jenkins, Ashutosh Chilkoti

    Valency is a fundamental principle to control macromolecular interactions and is used to target specific cell types by multivalent ligand–receptor interactions using self-assembled nanoparticle carriers. At the concentrations encountered in solid tumors upon systemic administration, these nanoparticles are, however, likely to show critical micelle concentration (CMC)-dependent disassembly and thus loss of function. To overcome this limitation, core-crosslinkable micelles of genetically encoded resilin-/elastin-like diblock polypeptides were recombinantly synthesized. The amphiphilic constructs were covalently photo-crosslinked through the genetically encoded unnatural amino acid para-azidophenylalanine in their hydrophobic block and they carried different anticancer ligands on their hydrophilic block: the wild-type tenth human fibronectin type III domain, a GRGDSPAS peptide—both targeting αvβ3 integrin—and an engineered variant of the third fibronectin type III domain of tenascin C that is a death receptor 5 agonist. Although uncrosslinked micelles lost most of their targeting ability below their CMC, the crosslinked analogues remained active at concentrations up to 1000-fold lower than the CMC, with binding affinities that are comparable to antibodies.


  • Microphase Separation of Resilin-like and Elastin-like Diblock Copolypeptides in Concentrated Solutions

    by Luis A. Navarro, Justin J. Ryan, Michael Dzuricky, Michael Gradzielski, Ashutosh Chilkoti, Stefan Zauscher

    Diblock copolymers are valued for their ability to form thin films with nanoscale features that typically reflect those of their microphase-separated structures in concentrated solution. Here, we show that such self-assembled structures can be easily formed with diblock copolymers composed of thermally responsive polypeptides, such as resilin-like polypeptides (RLP) and elastin-like polypeptides (ELP), by exploiting the inverse temperature transition behavior of ELPs in aqueous media. Specifically, we examine the self-assembly of a series of RLP-b-ELP diblock copolypeptides in concentrated aqueous solution (30 and 50 wt %) by small-angle X-ray scattering (SAXS). By systematically varying RLP block length and temperature (10–45 °C), we observed microphase separation into hexagonally packed cylinders and lamellae. By analyzing the observed order–order transitions (OOT) and order–disorder transitions (ODT), we determined that self-assembly in this system is primarily driven by polymer–solvent interactions. While these thermally responsive polymers showed clear ODTs and OOTs at certain temperatures, temperature only had a weak effect on the spacing of the resulting nanostructures. In contrast, we found that nanostructure spacing was far more sensitive to RLP block length. Finally, we used atomic force microscopy (AFM) to demonstrate that spin casting RLP-b-ELP diblock copolypeptides also produce nanostructured thin films with spacings that correlate with those in concentrated solution.


  • Top Cited Papers

    De novo engineering of intracellular condensates using artificial disordered proteins

    by Michael Dzuricky, Bradley A. Rogers, Abdulla Shahid, Paul S. Cremer, Ashutosh Chilkoti

    Phase separation of intrinsically disordered proteins (IDPs) is a remarkable feature of living cells to dynamically control intracellular partitioning. Despite the numerous new IDPs that have been identified, progress towards rational engineering in cells has been limited. To address this limitation, we systematically scanned the sequence space of native IDPs and designed artificial IDPs (A-IDPs) with different molecular weights and aromatic content, which exhibit variable condensate saturation concentrations and temperature cloud points in vitro and in cells. We created A-IDP puncta using these simple principles, which are capable of sequestering an enzyme and whose catalytic efficiency can be manipulated by the molecular weight of the A-IDP. These results provide a robust engineered platform for creating puncta with new, phase-separation-mediated control of biological function in living cells.


  • Genetically Encoded Stealth Nanoparticles of a Zwitterionic Polypeptide-Paclitaxel Conjugate Have a Wider Therapeutic Window than Abraxane in Multiple Tumor Models

    by Samagya Banskota, Soumen Saha, Jayanta Bhattacharyya, Nadia Kirmani, Parisa Yousefpour, Michael Dzuricky, Nikita Zakharov, Xinghai Li, Ivan Spasojevic, Kenneth Young, et al.

    Small-molecule therapeutics demonstrate sub-optimal pharmacokinetics and bioavailability due to their hydrophobicity and size. One way to overcome these limitations—and improve their efficacy—is to use “stealth” macromolecular carriers that evade uptake by the reticuloendothelial system. Although unstructured polypeptides are of increasing interest as macromolecular drug carriers, current recombinant polypeptides in the clinical pipeline typically lack stealth properties. We address this challenge by developing new unstructured polypeptides, called zwitterionic polypeptides (ZIPPs), that exhibit “stealth” behavior in vivo. We show that conjugating paclitaxel to a ZIPP imparts sufficient amphiphilicity to the polypeptide chain to drive its self-assembly into micelles, and increase its the half-life by 17-fold, and by 1.6-fold compared to non-stealth control. Treatment of mice bearing highly aggressive prostate or colon cancer with a single dose of ZIPP-paclitaxel nanoparticles leads to near-complete eradication of the tumor, and these nanoparticles have a wider therapeutic window than Abraxane—an FDA-approved taxane nanoformulation.


  • Open Access

    Intrinsically disordered proteins access a range of hysteretic phase separation behaviors

    by Felipe Garcia Quiroz, Nan K. Li, Stefan Roberts, Patrick Weber, Michael Dzuricky, Isaac Weitzhandler, Yaroslava G. Yingling, Ashutosh Chilkoti

    Salient nonequilibrium phase separation behaviors in intrinsically disordered proteins dictate phase separation–driven assembly.


  • Avidity and Cell Uptake of Integrin-Targeting Polypeptide Micelles is Strongly Shape-Dependent

    by Michael Dzuricky, Sinan Xiong, Patrick Weber, Ashutosh Chilkoti

    We describe a genetically encoded micelle for targeted delivery consisting of a diblock polypeptide with segments derived from repetitive protein motifs inspired by Drosophila melanogaster Rec-1 resilin and human tropoelastin with a C-terminal fusion of an integrin-targeting fibronectin type III domain. By systematically varying the weight fraction of the hydrophilic elastin-like polypeptide (ELP) block and molecular weight of the diblock polypeptide, we designed micelles of different morphologies that modulate the binding avidity of the human wild-type 10th fibronectin domain (Fn3) as a function of shape. We show that wormlike micelles that present the Fn3 domain have a 1000-fold greater avidity for the αvβ3 receptor compared to the monomer ligand and an avidity that is greater than a clinically relevant antibody that is driven by their multivalency. The amplified avidity of these micelles leads to significantly increased cellular internalization, a feature that may have utility for the intracellular delivery of drugs that are loaded into the core of these micelles.


  • Genetically Encoded Cholesterol-Modified Polypeptides

    by Davoud Mozhdehi, Kelli M. Luginbuhl, Michael Dzuricky, Simone A. Costa, Sinan Xiong, Fred C. Huang, Mae M. Lewis, Stephanie R. Zelenetz, Christian D. Colby, Ashutosh Chilkoti

    Biological systems use post-translational modifications (PTMs) to control the structure, location, and function of proteins after expression. Despite the ubiquity of PTMs in biology, their use to create genetically encoded recombinant biomaterials is limited. We have utilized a natural lipidation PTM (hedgehog-mediated cholesterol modification of proteins) to create a class of hybrid biomaterials called cholesterol-modified polypeptides (CHaMPs) that exhibit programmable self-assembly at the nanoscale. To demonstrate the biomedical utility of CHaMPs, we used this approach to append cholesterol to biologically active peptide exendin-4 that is an approved drug for the treatment of type II diabetes. The exendin-cholesterol conjugate self-assembled into micelles, and these micelles activate the glucagon-like peptide-1 receptor with a potency comparable to that of current gold standard treatments.


  • Active Targeting of Cancer Cells by Nanobody Decorated Polypeptide Micelle with Bio-orthogonally Conjugated Drug

    by Simone A. Costa, Davoud Mozhdehi, Michael J. Dzuricky, Farren J. Isaacs, Eric M. Brustad, Ashutosh Chilkoti

    Polypeptides are exceptionally promising carriers for chemotherapeutics: they have minimal toxicity, can be recombinantly synthesized with precise control over molecular weight, and enhance drug pharmacokinetics as self-assembled nanoparticles. Polypeptide-based systems also provide the ability to achieve active targeting with genetically encoded targeting ligands. While passive targeting promotes accumulation of nanocarriers in solid tumors, active targeting provides an additional layer of tunable control and widens the therapeutic window. However, fusion of most targeting proteins to polypeptide carriers exposes the limitations of this approach: the residues that are used for drug attachment are also promiscuously distributed on protein surfaces. To solve this problem, we incorporate an unnatural amino acid, p-acetylphenylalanine, to provide a biorthogonal ketone for attachment of doxorubicin in the presence of reactive amino acids in a nanobody-targeted, elastin-like polypeptide nanoparticle. These particles exhibit significantly greater cytotoxicity than non-targeted controls in multiple cancer cell lines. We present here a universal methodology for the site-specific attachment of extrinsic moieties to polypeptide drug delivery systems without cross-reactivity to fused targeting domains.


  • Convergence of Artificial Protein Polymers and Intrinsically Disordered Proteins

    by Michael Dzuricky, Stefan Roberts, Ashutosh Chilkoti

    A flurry of research in recent years has revealed the molecular origins of many membraneless organelles to be the liquid phase separation of intrinsically disordered proteins (IDPs). Consequently, protein disorder has emerged as an important driver of intracellular compartmentalization by providing specialized microenvironments chemically distinct from the surrounding medium. Though the importance of protein disorder and its relationship to intracellular phase behavior are clear, a detailed understanding of how such phase behavior can be predicted and controlled remains elusive. While research in IDPs has largely focused on the implications of structural disorder on cellular function and disease, another field, that of artificial protein polymers, has focused on the de novo design of protein polymers with controllable material properties. A subset of these polymers, specifically those derived from structural proteins such as elastin and resilin, are also disordered sequences that undergo liquid–liquid phase separation. This phase separation has been used in a variety of biomedical applications, and researchers studying these polymers have developed methods to precisely characterize and tune their phase behavior. Despite their disparate origins, both fields are complementary as they study the phase behavior of intrinsically disordered polypeptides. This Perspective hopes to stimulate collaborative efforts by highlighting the similarities between these two fields and by providing examples of how such collaboration could be mutually beneficial.